Danielle Brander, MD, discusses the current treatment landscape in the frontline setting for patients with chronic lymphocytic leukemia.
Videos
Krishnansu S. Tewari, MD, discusses the excitement around immunotherapy in cervical cancer.
Eric Smith, MD, PhD, discusses challenges with CAR T-cell therapy as a treatment option for multiple myeloma. While studies have shown CD19 CAR T cells and BCMA CAR T cells have durable responses in this patient population, patients still relapse over time.
Hassane M. Zarour, MD, discusses the addition of antibiotics to immunotherapy treatment in patients with melanoma.
Riccardo Lencioni, MD, discusses how to successfully integrate Liver Imaging Reporting and Data Systems their clinical practice.<br />
Masatoshi Kudo, MD, PhD, discusses the potential for systemic therapy in the adjuvant setting of hepatocellular carcinoma. While current trials are investigating this therapy in advanced stage HCC, Kudo believes it could benefit patients following a surgery resecting an aberration.
Fabrice Barlesi, MD, discusses the importance of molecular testing in patients with nonsquamous non–small cell lung cancer during the World Conference on Lung Cancer in Toronto, Canada.
Jonathon B. Cohen, MD, discusses findings from a study of polatuzumab vedotin, an anti-CD79b antibody-drug conjugate, with bendamustine and rituximab in patients with aggressive lymphomas.
David Spigel, MD, medical oncologist and Chief Scientific Officer at Sarah Cannon Research Institute, discusses the updated results for the PACIFIC trial, a randomized phase III trial investigating the addition of durvalumab (Imfinzi) to chemoradiation versus placebo in patients with unresectable stage III lung cancer.
Robert C. Doebele, MD, PhD, discusses resistance in patients with ROS1-positive lung cancer.
